Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Reza Elaidi; A. Harbaoui; B. Beuselinck; J. C. Eymard; A. Bamias; E. De Guillebon; C. Porta; Y. Vano; C. Linassier; P. R. Debruyne; M. Gross-Goupil; A. Ravaud; M. Aitelhaj; G. Marret; S. Oudard

doi:10.1093/annonc/mdu552

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Reza Elaidi^*
, A. Harbaoui
, B. Beuselinck
, J. C. Eymard
, A. Bamias
, E. De Guillebon
, C. Porta
, Y. Vano
, C. Linassier
, P. R. Debruyne
, M. Gross-Goupil
, A. Ravaud
, M. Aitelhaj
, G. Marret
, S. Oudard

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.

Original language	English
Pages (from-to)	378-385
Number of pages	8
Journal	Annals of Oncology
Volume	26
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mdu552
Publication status	Published - 1 Feb 2015
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Keywords

Kidney cancer
Mammalian target of rapamycin (mTOR)
Sequence
Tyrosine kinase inhibitor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdu552

Cite this

Elaidi, R., Harbaoui, A., Beuselinck, B., Eymard, J. C., Bamias, A., De Guillebon, E., Porta, C., Vano, Y., Linassier, C., Debruyne, P. R., Gross-Goupil, M., Ravaud, A., Aitelhaj, M., Marret, G., & Oudard, S. (2015). Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Annals of Oncology, 26(2), 378-385. https://doi.org/10.1093/annonc/mdu552

@article{06bd683d79fa43e796fc599a922163a0,

title = "Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma",

abstract = "In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.",

keywords = "Kidney cancer, Mammalian target of rapamycin (mTOR), Sequence, Tyrosine kinase inhibitor",

author = "Reza Elaidi and A. Harbaoui and B. Beuselinck and Eymard, \{J. C.\} and A. Bamias and \{De Guillebon\}, E. and C. Porta and Y. Vano and C. Linassier and Debruyne, \{P. R.\} and M. Gross-Goupil and A. Ravaud and M. Aitelhaj and G. Marret and S. Oudard",

year = "2015",

month = feb,

day = "1",

doi = "10.1093/annonc/mdu552",

language = "English",

volume = "26",

pages = "378--385",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "2",

}

Elaidi, R, Harbaoui, A, Beuselinck, B, Eymard, JC, Bamias, A, De Guillebon, E, Porta, C, Vano, Y, Linassier, C, Debruyne, PR, Gross-Goupil, M, Ravaud, A, Aitelhaj, M, Marret, G & Oudard, S 2015, 'Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma', Annals of Oncology, vol. 26, no. 2, pp. 378-385. https://doi.org/10.1093/annonc/mdu552

TY - JOUR

T1 - Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

AU - Elaidi, Reza

AU - Harbaoui, A.

AU - Beuselinck, B.

AU - Eymard, J. C.

AU - Bamias, A.

AU - De Guillebon, E.

AU - Porta, C.

AU - Vano, Y.

AU - Linassier, C.

AU - Debruyne, P. R.

AU - Gross-Goupil, M.

AU - Ravaud, A.

AU - Aitelhaj, M.

AU - Marret, G.

AU - Oudard, S.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.

AB - In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.

KW - Kidney cancer

KW - Mammalian target of rapamycin (mTOR)

KW - Sequence

KW - Tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/84925304746

U2 - 10.1093/annonc/mdu552

DO - 10.1093/annonc/mdu552

M3 - Article

C2 - 25467013

AN - SCOPUS:84925304746

SN - 0923-7534

VL - 26

SP - 378

EP - 385

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Abstract

ASJC Scopus subject areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this